Results for this period
Interim period (second quarter)1 February 2026 to 31 July 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The main costs related to obtaining approval for partial changes to the manufacturing and marketing approval for アクーゴ®. Research and development expenses of ¥1,226 million were recorded. Foreign exchange gains of ¥185 million arose from fluctuations in exchange rates.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 February 2026 to 31 July 2026 |
| Operating profit | ¥-1,909 million |
| Ordinary income | ¥-1,730 million |
| Profit attributable to owners of the parent | ¥-1,791 million |
| Net income per share | -¥22.95 |
| Equity ratio | End of the current fiscal period 84 / End of previous period 85.4 |
| Total assets | ¥13,645 million |
| Net assets | ¥11,724 million |
| Cash flows from operating activities | ¥-2,136 million |
| Cash flows from investing activities | ¥78 million |
| Cash flows from financing activities | ¥-111 million |
| Cash and cash equivalents at end of period | ¥12,677 million |
| Full-year earnings forecast | Net Sales ¥396 million / Operating profit ¥-5,229 million / Ordinary income ¥-5,074 million / Net income ¥-5,133 million |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Depreciation and amortization | ¥27,308 thousand |
| Breakdown of extraordinary income (loss) | Category Extraordinary income / Item Gain on reversal of subscription rights to shares / Amount ¥1,478 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 78,058,883 shares |
| Treasury Shares at Period-End | 540 shares |
| Factors Behind Changes in Business Performance | The main costs related to obtaining approval for partial changes to the manufacturing and marketing approval for アクーゴ®. Research and development expenses of ¥1,226 million were recorded. Foreign exchange gains of ¥185 million arose from fluctuations in exchange rates. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main costs related to obtaining approval for partial changes to the manufacturing and marketing approval for アクーゴ®. Research and development expenses of ¥1,226 million were recorded. Foreign exchange gains of ¥185 million arose from fluctuations in exchange rates.